Roth Adjusts Ests on Galena (GALE) Following FY15 Net Revs Outlook; 2015 Will be 'Busy Year' for Company
Tweet Send to a Friend
Roth Capital is updating estimates on Galena Biopharma (Nasdaq: GALE) after the company issued FY15 net revenue guidance of $15 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
